Epigenetics In Neurodegeneration is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes. PMID: 34830163
Epigenetics refers to heritable changes in gene expression that occur without alterations to the underlying DNA sequence. In the central [@tracing]
nervous system, epigenetic are essential for neuronal differentiation, synaptic plasticity, memory formation, and the [@role]
maintenance of neuronal identity throughout life. Dysregulation of the epigenetic landscape has emerged as a critical contributor to the [@exploring]
pathogenesis of neurodegenerative, including Alzheimer's disease, [Parkinson's disease](/diseases/parkinsons-disease), amyotrophic lateral sclerosis, [@hyperglycaemiainduced]
frontotemporal dementia, and Huntington's disease.[@foxn] [@smith2015]
Five principal epigenetic govern chromatin state and gene regulation: (1) DNA methylation and hydroxymethylation, (2) histone [^7]
post-translational modifications, (3) chromatin remodeling, (4) non-coding RNA regulation, and (5) RNA modifications. These [^8]
operate in concert to control access to genetic information, and their perturbation in [neurons](/entities/neurons) leads to aberrant expression of genes [^9]
involved in protein aggregation, neuroinflammation, synaptic dysfunction, and [apoptosis](/entities/apoptosis) [@foxn]. [^10]
Epigenetics In Neurodegeneration is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes. PMID: 34830163
Epigenetics refers to heritable changes in gene expression that occur without alterations to the underlying DNA sequence. In the central [@tracing]
nervous system, epigenetic are essential for neuronal differentiation, synaptic plasticity, memory formation, and the [@role]
maintenance of neuronal identity throughout life. Dysregulation of the epigenetic landscape has emerged as a critical contributor to the [@exploring]
pathogenesis of neurodegenerative, including Alzheimer's disease, [Parkinson's disease](/diseases/parkinsons-disease), amyotrophic lateral sclerosis, [@hyperglycaemiainduced]
frontotemporal dementia, and Huntington's disease.[@foxn] [@smith2015]
Five principal epigenetic govern chromatin state and gene regulation: (1) DNA methylation and hydroxymethylation, (2) histone [^7]
post-translational modifications, (3) chromatin remodeling, (4) non-coding RNA regulation, and (5) RNA modifications. These [^8]
operate in concert to control access to genetic information, and their perturbation in [neurons](/entities/neurons) leads to aberrant expression of genes [^9]
involved in protein aggregation, neuroinflammation, synaptic dysfunction, and [apoptosis](/entities/apoptosis) [@foxn]. [^10]
The reversibility of epigenetic modifications makes them particularly attractive therapeutic targets. Unlike genetic mutations, epigenetic [@yadav2025]
changes can potentially be pharmacologically corrected, offering new avenues for disease-modifying treatments in neurodegeneration.[@tracing] [@sokpor2017]
DNA methylation is the covalent addition of a methyl group to the 5-carbon position of cytosine, primarily at CpG dinucleotides, catalyzed [@frost2014]
by DNA methyltransferases (DNMTs). The methyl donor is S-adenosyl-L-methionine (SAM). In the brain, approximately 75-80% of CpG sites are [@salta2016]
methylated, with distinct patterns in neurons versus glial cells. DNA methylation at gene promoters typically represses transcription by [@horvath2013]
recruiting methyl-CpG binding domain (MBD) and preventing transcription factor binding [@tracing]. [@shireby2020]
Active DNA demethylation occurs through the ten-eleven translocation (TET) enzymes, which sequentially oxidize 5-methylcytosine (5mC) to [@magistri2016] PMID: 36432638
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). Notably, 5hmC is highly enriched in the brain — [@nakamura2025]
approximately 10-fold higher than in peripheral tissues — and is particularly abundant in neurons, where it marks active genes and
enhancers.[@role]
Large-scale epigenome-wide association studies (EWAS) have identified widespread DNA methylation alterations in Alzheimer's disease brains. The landmark 2014 studies by De Jager et al. and Lunnon et al., published simultaneously in Nature Neuroscience, identified methylation changes at 71 CpG sites significantly associated with AD pathology burden, including loci at ANK1, BIN1, RHBDF2, ABCA7, and other genes. The ANK1 locus showed consistent hypermethylation in cortical regions but not in the cerebellum, a region relatively spared in AD.4,5</a>
A 2021 meta-analysis by Smith et al. combining six EWAS datasets (N=1,453 individuals) identified 220 CpGs associated with AD neuropathology
across cortex, annotated to 121 genes, of which 84 had not been previously reported.[@smith2015]
Specific AD-related genes show characteristic methylation changes:
The C9orf72 hexanucleotide repeat expansion, the most common genetic cause of both ALS and FTD, shows striking epigenetic regulation:
Histones are subject to extensive post-translational modifications including acetylation, methylation, phosphorylation, ubiquitination,
SUMOylation, lactylation, and crotonylation. These modifications form a "histone code" that governs chromatin accessibility and gene
expression. In neurons, [histone modifications](/entities/histone-modifications) are dynamically regulated during learning, memory formation, and synaptic plasticity, and
their dysregulation contributes to neurodegeneration.[^9]
Histone acetylation, catalyzed by histone acetyltransferases (HATs) and removed by histone deacetylases (HDACs, see [protein acetylation and
[HDAC](/entities/hdac-enzymes), generally promotes an open chromatin configuration and active gene transcription [@role]
.
In Alzheimer's Disease:
Histone methylation involves the addition of one to three methyl groups to lysine or arginine residues, with effects on gene expression
depending on the specific residue and degree of methylation [@exploring].
Key marks altered in neurodegeneration:
Histone phosphorylation, particularly at H3S10 and H3S28, is involved in chromatin condensation, DNA damage response, and transcriptional
activation. Increased H3 phosphorylation has been documented in AD brains, potentially reflecting aberrant neuronal cell cycle re-entry — PMID: 35813941
a known phenomenon in vulnerable neurons in AD [@hyperglycaemiainduced].
ATP-dependent chromatin remodeling complexes use the energy of ATP hydrolysis to reposition, eject, or restructure nucleosomes, controlling
gene accessibility. The BRG1/BRM-associated factor (BAF or mSWI/SNF) complex, comprising at least 15 subunits (~2 MDa), plays a critical
role in neuronal development, maturation, and function [@smith2015]
.
Neural progenitor-specific BAF complexes (npBAF) are essential for controlling neural progenitor cell division, while neuron-specific BAF
(nBAF) complexes are necessary for the maturation of postmitotic neuronal phenotypes. Subunit switching from npBAF to nBAF is a fundamental
mechanism of neuronal differentiation.[@sokpor2017]
Frost et al. (2014) demonstrated in Nature Neuroscience that tau//tau promotes neurodegeneration through global chromatin
relaxation. Using Drosophila and mouse models, they showed widespread loss of heterochromatin in tauopathies, with oxidative stress
and DNA damage serving as a mechanistic link between tau and heterochromatin loss. Genetic rescue of heterochromatin loss substantially
reduced neurodegeneration, establishing chromatin relaxation as a causal mechanism in tau-mediated neuronal death.[@frost2014]
MicroRNAs (miRNAs) are small non-coding RNAs (~22 nucleotides) that regulate gene expression post-transcriptionally by binding to the
3'-untranslated regions of target mRNAs (see [non-coding RNA in neurodegeneration). Multiple miRNAs are dysregulated in neurodegenerative
[^7].
Key miRNAs in Alzheimer's Disease:
Long non-coding RNAs (lncRNAs, >200 nucleotides) regulate gene expression through chromatin modulation, post-transcriptional regulation, and
protein complex organization [^8].
Key lncRNAs in neurodegeneration:
The epigenetic clock, developed by Steve Horvath in 2013, uses DNA methylation patterns at 353 CpG sites to estimate biological age with
remarkable accuracy (correlation with chronological age of 0.97, median absolute error of 2.9 years). The concept that epigenetic age can
deviate from chronological age — termed "epigenetic age acceleration" — has profound implications for understanding neurodegeneration as a PMID: 24905038
disease of accelerated biological aging.[@horvath2013]
However, standard epigenetic clocks perform suboptimally in brain tissue. Shireby et al. (2020) developed DNAmClockCortical, a
brain-specific epigenetic clock built from over 1,000 human cortex samples, which dramatically outperforms existing clocks for cortical age
prediction.[@shireby2020]
Multiple epigenetic clocks have been associated with AD pathology. The Cortical clock shows substantially stronger associations: each
standard deviation increase in Cortical age corresponds to a 90% greater likelihood of pathologic AD, compared to approximately 30% for the
Hannum, Horvath, and PhenoAge clocks [^9].
Recent cell-type-specific analyses (2024-2025) have revealed that glial cells — particularly [microglia](/cell-types/microglia-neuroinflammation) — age
fastest in AD patients, suggesting that accelerated aging of specific cell types plays a critical role in neurodegeneration [^10].
The catalytic subunit of PRC2 that trimethylates H3K27. [EZH2 modulates [microglial//microglia activation, triggering release of
pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha). The EZH2 inhibitor GSK-343 has shown neuroprotective properties against
[dopaminergic degeneration in PD models by regulating the NF-kappaB/IkappaB-alpha pathway.[@yadav2025]
HDAC inhibitors represent the most advanced class of epigenetic therapeutics for neurodegeneration:
Pan-HDAC inhibitors:
BET (BRD2, BRD3, BRD4) function as "readers" of acetylated histones and interact with transcription factors to regulate proinflammatory gene expression:
A rapidly advancing frontier involves CRISPR-based epigenome editing for neurological disorders:
The MAPT gene], encoding tau protein//tau, is subject to epigenetic regulation through promoter and intron methylation:
The SNCA gene, encoding [alpha-synuclein//alpha, has a well-characterized methylation-dependent transcriptionally active region in intron 1:
The C9orf72 hexanucleotide repeat expansion (GGGGCC) shows a remarkable epigenetic paradox:
Single-cell epigenomics (2024-2025): Single-cell ATAC-seq and methylation profiling have revealed that microglia//microglia and [astrocytes](/entities/astrocytes) show the most pronounced epigenetic age acceleration in AD, preceding neuronal loss and suggesting that glial epigenetic dysfunction is an early event. PMID: 34239129
5hmC and TET3 in AD (2025): Profiling of 1,079 brains identified 2,821 differentially hydroxymethylated regions in AD, with TET3 overexpression attenuating neurodegeneration.[@role]
Novel histone modifications (2024): Discovery of histone lactylation and crotonylation alterations in AD brains, expanding the repertoire of epigenetic marks implicated in neurodegeneration.
CRISPR epigenome editing advances (2025): The RENDER platform and virus-like particle delivery of CRISPR epigenome editors demonstrated durable gene silencing in neurons, with applications to tau and alpha-synuclein reduction.[@nakamura2025]
bfe67bb53c3c532ef4237fa3323691ae27404769
The study of Epigenetics In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this mechanism.
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 18 references |
| Replication | 33% |
| Effect Sizes | 50% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 75% |
Overall Confidence: 62%